Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia
Ended Project Grant Awarded Last action
- Award ID
- R44CA224848
- Recipient
-
Biofluidica, Inc. UEI LFTNJ5WJS5V8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,743,470
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $556,708 | |
| Amendment | -$126,839 | |
| Amendment | $126,839 | |
| Amendment | $837,994 | |
| Amendment | $0 | |
| Original award | $348,768 |
Quick answers
Who received award R44CA224848?
R44CA224848 was awarded to Biofluidica, Inc. by National Cancer Institute (National Institutes of Health) on July 18, 2018.
How much is award R44CA224848 worth?
$1,743,470 has been obligated on R44CA224848.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award